Millennium Management’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-5,807
| Closed | -$88.3K | – | 6474 |
|
|
2025
Q1 | $88.3K | Sell |
5,807
-7,340
| -56% | -$111K | ﹤0.01% | 5454 |
|
|
2024
Q4 | $241K | Sell |
13,147
-3,184
| -19% | -$34.7K | ﹤0.01% | 5195 |
|
|
2024
Q3 | $181K | Buy |
16,331
+32
| +0.2% | +$375 | ﹤0.01% | 5476 |
|
|
2024
Q2 | $151K | Sell |
16,299
-2,085
| -11% | -$49.7K | ﹤0.01% | 5228 |
|
|
2024
Q1 | $602K | Buy |
18,384
+5,407
| +42% | +$140K | ﹤0.01% | 4697 |
|
|
2023
Q4 | $347K | Sell |
12,977
-8,537
| -40% | -$353K | ﹤0.01% | 4881 |
|
|
2023
Q3 | $1.3M | Buy |
21,514
+824
| +4% | +$77.3K | ﹤0.01% | 3971 |
|
|
2023
Q2 | $2.11M | Buy |
20,690
+20,343
| +5,863% | +$2.8M | ﹤0.01% | 3443 |
|
|
2023
Q1 | $61K | Sell |
347
-162
| -32% | -$54.3K | ﹤0.01% | 5562 |
|
|
2022
Q4 | $197K | Buy |
+509
| New | +$193K | ﹤0.01% | 5345 |
|
|
2022
Q3 | – | Sell |
-21,616
| Closed | -$7.11M | – | 7587 |
|
|
2022
Q2 | $7.11M | Buy |
+21,616
| New | +$7.58M | ﹤0.01% | 2433 |
|
|
2021
Q4 | – | Sell |
-1,002
| Closed | -$557K | – | 7485 |
|
|
2021
Q3 | $557K | Buy |
+1,002
| New | +$503K | ﹤0.01% | 5250 |
|
|
2021
Q2 | – | Sell |
-1,395
| Closed | -$1.09M | – | 7227 |
|
|
2021
Q1 | $1.09M | Sell |
1,395
-3,280
| -70% | -$2.25M | ﹤0.01% | 4137 |
|
|
2020
Q4 | $2.55M | Buy |
4,675
+4,291
| +1,117% | +$2.25M | ﹤0.01% | 3039 |
|
|
2020
Q3 | $176 | Sell |
384
-2,565
| -87% | -$1.49M | ﹤0.01% | 4103 |
|
|
2020
Q2 | $1.81M | Buy |
+2,949
| New | +$1.63M | ﹤0.01% | 2603 |
|
|
2020
Q1 | – | Sell |
-1,103
| Closed | -$639K | – | 4615 |
|
|
2019
Q4 | $639K | Buy |
+1,103
| New | +$774K | ﹤0.01% | 3231 |
|
|
2019
Q3 | – | Sell |
-1,572
| Closed | -$1.22M | – | 4625 |
|
|
2019
Q2 | $1.22M | Buy |
1,572
+864
| +122% | +$607K | ﹤0.01% | 2688 |
|
|
2019
Q1 | $500K | Sell |
708
-8,024
| -92% | -$4.8M | ﹤0.01% | 3269 |
|
|
2018
Q4 | $4.09M | Sell |
8,732
-206
| -2% | -$133K | 0.01% | 1723 |
|
|
2018
Q3 | $7.71M | Buy |
8,938
+7,330
| +456% | +$5.29M | 0.01% | 1494 |
|
|
2018
Q2 | $1.11M | Buy |
+1,608
| New | +$817K | ﹤0.01% | 2772 |
|
|
2018
Q1 | – | Sell |
-3,117
| Closed | -$1.37M | – | 4163 |
|
|
2017
Q4 | $1.37M | Buy |
3,117
+2,579
| +479% | +$1.18M | ﹤0.01% | 2508 |
|
|
2017
Q3 | $265K | Sell |
538
-188
| -26% | -$94.1K | ﹤0.01% | 3114 |
|
|
2017
Q2 | $402K | Buy |
+726
| New | +$461K | ﹤0.01% | 2914 |
|
|
2017
Q1 | – | Sell |
-455
| Closed | -$152K | – | 3908 |
|
|
2016
Q4 | $152K | Buy |
+455
| New | +$146K | ﹤0.01% | 3139 |
|
|
2016
Q3 | – | Sell |
-12,267
| Closed | -$2.12M | – | 3684 |
|
|
2016
Q2 | $2.12M | Buy |
12,267
+1,405
| +13% | +$306K | ﹤0.01% | 1751 |
|
|
2016
Q1 | $2.43M | Sell |
10,862
-10,840
| -50% | -$3.24M | 0.01% | 1669 |
|
|
2015
Q4 | $13.2M | Sell |
21,702
-1,142
| -5% | -$627K | 0.03% | 781 |
|
|
2015
Q3 | $11.8M | Buy |
22,844
+2,821
| +14% | +$1.89M | 0.02% | 841 |
|
|
2015
Q2 | $8.76M | Buy |
20,023
+13,801
| +222% | +$5.33M | 0.02% | 1060 |
|
|
2015
Q1 | $2.25M | Buy |
6,222
+5,227
| +525% | +$1.98M | ﹤0.01% | 1880 |
|
|
2014
Q4 | $357K | Buy |
+995
| New | +$320K | ﹤0.01% | 3238 |
|
Other funds holding TVRD
SPC
6CM
FCM
Millennium Management's TVRD Position: Q2 2025 in Review
Millennium Management sold out of Tvardi Therapeutics (TVRD) in Q2 2025, closing a stake of 5,807 shares — an estimated $88.3K sold.
Millennium Management first reported a position in TVRD in Q4 2014 and held it in 33 quarters. The position peaked at $13.2M in Q4 2015. 56 funds tracked by Wall St. Rank hold TVRD as of Q2 2025.
- Millennium Management reported no remaining Tvardi Therapeutics position as of Q2 2025 after selling out during the quarter.
- Millennium Management sold 5,807 Tvardi Therapeutics shares in Q2 2025, an estimated $88.3K.
- Millennium Management first reported a position in Tvardi Therapeutics in Q4 2014 and held it in 33 quarters.
- Millennium Management's Tvardi Therapeutics position peaked at $13.2M in Q4 2015.
- 56 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2025.
Based on Millennium Management's 13F filing for Q2 2025, filed 14 Aug 2025.